CBD Panel Discussion: Bridging the gap between science and regulation

In 2018, CBD sales in the United States were estimated at $534 million, according to the Hemp Business Journal. USA projections in 2025 are expected to reach an estimated $25 Billion.

To many, CBD offers a variety of benefits when ingested, inhaled, or applied topically – with product marketing and advertising claims similarly ranging from calming effects to pain relief. Patient use fuels the research drive, which is rapidly increasing, and recent changes in the United States have paved the way for exciting new work.

Both the safety and the potential therapeutic uses of these products need to be assessed for a range of indications. With the rapid expansion of new products, novel methods of use, and growing populations using these products for medical indications or for nonmedical use, regulatory restrictions are a major contributing factor to the limited data published addressing the most urgent questions on the potential effectiveness of products on the market for certain indications.

Asa Waldstein joins the Atlantia team to discuss how to use clinical data for marketing purposes to overcome regulatory hurdles that many CBD companies are encountering when commercializing their innovations.

Watch it on demand now!

The speakers

Ted Dinan
Medical Director at Atlantia Clinical Trials
Emeritus Professor of Psychiatry and a Principal Investigator in APC Microbiome Ireland at University College Cork. He has been mentioned as part of the Highly Cited Researchers, by Clarivate Analytics. and Expertscape. Prof. Dinan has promoted the concept of Psychobiotics, probiotics that have a mental health benefits.

Asa Waldstein_Headshot (1)
Asa Waldstein

Principal at Supplement Advisory Group
Asa Waldstein is a Certified Clinical Herbalist and a 20-year dietary supplement executive who is principal of the consulting company Supplement Advisory Group, a boutique group focusing on marketing risk analysis and practical marketing solutions for the web and social media. He is the founder and host of Asa's Regulatory Education Series, a free educational platform focusing on GMP compliance, enforcement trends, and marketing tips for the supplement and hemp industries. He chairs the American Herbal Products Association's (AHPA) Cannabis Committee. Learn more and contact him at AsaWaldstein.com.

The moderator

Meredith Holt
Meredith Holt

National Sales Manager at Atlantia Clinical Trials
Meredith Holt is the National Sales Manager at Atlantia Clinical Trials and 25-year veteran of the pharmaceutical and nutraceutical industries. Meredith is Certified Clinical Nutritionist (CCN) and holds master’s degrees in both exercise physiology from Northeastern Illinois University, and Clinical Nutrition from New York Chiropractic College. She has previously worked with CBD manufacturers in developing an e-commerce platform where practitioners can recommend CBD to their patients. 

Watch the panel on-demand

in collaboration with

Supplement_Advisory_Group_Final_Logo-01 YES